X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (34716) 34716
Book Review (7192) 7192
Publication (2295) 2295
Book Chapter (230) 230
Book / eBook (145) 145
Conference Proceeding (91) 91
Newsletter (82) 82
Magazine Article (34) 34
Newspaper Article (12) 12
Dissertation (11) 11
Transcript (6) 6
Trade Publication Article (4) 4
Reference (3) 3
Data Set (2) 2
Government Document (1) 1
Paper (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (31598) 31598
humans (28354) 28354
female (14727) 14727
male (14723) 14723
middle aged (10413) 10413
adult (9562) 9562
recombinant proteins (9212) 9212
animals (9101) 9101
recombinant proteins - therapeutic use (7671) 7671
aged (6842) 6842
treatment outcome (5646) 5646
recombinant proteins - adverse effects (4616) 4616
recombinant proteins - administration & dosage (3860) 3860
mice (3747) 3747
oncology (3722) 3722
abridged index medicus (3555) 3555
immunology (3333) 3333
hematology (3298) 3298
therapy (3131) 3131
interferon-alpha - therapeutic use (3048) 3048
interferon-alpha - adverse effects (3001) 3001
pharmacology & pharmacy (2916) 2916
adolescent (2851) 2851
drug therapy, combination (2796) 2796
proteins (2706) 2706
health aspects (2562) 2562
care and treatment (2506) 2506
analysis (2441) 2441
cancer (2319) 2319
dose-response relationship, drug (2272) 2272
research (2252) 2252
time factors (2250) 2250
hepatitis c, chronic - drug therapy (2222) 2222
erythropoietin - therapeutic use (2184) 2184
antiviral agents - therapeutic use (2174) 2174
recombinant proteins - pharmacology (2071) 2071
expression (1985) 1985
medicine, research & experimental (1985) 1985
biotechnology & applied microbiology (1968) 1968
interferon-alpha - administration & dosage (1965) 1965
biochemistry & molecular biology (1907) 1907
recombinant (1889) 1889
child (1883) 1883
drug administration schedule (1881) 1881
antiviral agents - adverse effects (1873) 1873
surgery (1734) 1734
prospective studies (1715) 1715
risk factors (1713) 1713
recombinant proteins - metabolism (1697) 1697
gastroenterology & hepatology (1681) 1681
interferon (1676) 1676
rats (1656) 1656
polyethylene glycols - therapeutic use (1645) 1645
drug therapy (1635) 1635
aged, 80 and over (1627) 1627
retrospective studies (1624) 1624
ribavirin - therapeutic use (1624) 1624
anemia (1604) 1604
safety (1574) 1574
transplantation (1526) 1526
medicine & public health (1488) 1488
recombinant fusion proteins - therapeutic use (1479) 1479
chemotherapy (1466) 1466
recombinant proteins - genetics (1465) 1465
anemia - drug therapy (1461) 1461
recombinant-human-erythropoietin (1451) 1451
medicine, general & internal (1448) 1448
gene expression (1431) 1431
double-blind method (1404) 1404
erythropoietin (1401) 1401
young adult (1385) 1385
follow-up studies (1384) 1384
immunotherapy (1350) 1350
antibodies (1342) 1342
antineoplastic combined chemotherapy protocols - therapeutic use (1317) 1317
clinical trials (1296) 1296
hepatitis c (1289) 1289
article (1261) 1261
double-blind (1248) 1248
clinical trials as topic (1241) 1241
medicine (1239) 1239
cells (1235) 1235
efficacy (1227) 1227
polyethylene glycols - adverse effects (1227) 1227
urology & nephrology (1214) 1214
research article (1210) 1210
antineoplastic combined chemotherapy protocols - adverse effects (1205) 1205
ribavirin - adverse effects (1196) 1196
trial (1195) 1195
physiological aspects (1192) 1192
cell biology (1190) 1190
erythropoietin - adverse effects (1189) 1189
ribavirin (1186) 1186
infection (1178) 1178
vaccines (1166) 1166
antineoplastic agents - adverse effects (1158) 1158
in-vivo (1139) 1139
anemia - etiology (1130) 1130
disease models, animal (1103) 1103
endocrinology & metabolism (1096) 1096
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (87) 87
UofT at Mississauga - Stacks (28) 28
UofT at Scarborough - Stacks (23) 23
UTL at Downsview - May be requested (16) 16
Engineering & Comp. Sci. - Stacks (13) 13
St. Michael's College (John M. Kelly) - 2nd Floor (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
St. Augustine's Seminary - Stacks (8) 8
Law (Bora Laskin) - Stacks (6) 6
Robarts - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Earth Sciences (Noranda) - Stacks (5) 5
Regis College - Stacks (4) 4
Online Resources - Online (3) 3
Victoria University E.J. Pratt - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Gerstein Science - Searching (1) 1
OISE - Stacks (1) 1
Physics - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33606) 33606
German (320) 320
Japanese (227) 227
French (223) 223
Spanish (220) 220
Chinese (150) 150
Russian (99) 99
Italian (67) 67
Polish (48) 48
Czech (30) 30
Hungarian (28) 28
Dutch (18) 18
Serbian (18) 18
Portuguese (14) 14
Danish (11) 11
Korean (11) 11
Swedish (7) 7
Bulgarian (5) 5
Norwegian (5) 5
Slovak (5) 5
Ukrainian (5) 5
Finnish (4) 4
Turkish (4) 4
Croatian (3) 3
Hebrew (3) 3
Romanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Hepatology, ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1336 - 1346
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection | Index Medicus
Journal Article